Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo (Q87427205)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23055414%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23055414%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

social anxiety disorder

1 reference

Sara I J Schutters

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23055414%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Harold J G M van Megen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23055414%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

J Frederieke Van Veen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23055414%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Koen R J Schruers

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23055414%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Herman G M Westenberg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23055414%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

1 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23055414%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

published in

Human Psychopharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23055414%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23055414%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23055414%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

72-76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23055414%20AND%20SRC:MED&resulttype=core&format=json

Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group

10 March 2020

cites work

1 reference

7 January 2021

A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder

1 reference

7 January 2021

What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?

1 reference

7 January 2021

Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain

1 reference

7 January 2021

A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine

1 reference

7 January 2021

The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission

1 reference

7 January 2021

Mirtazapine substitution in SSRI-induced sexual dysfunction.

1 reference

7 January 2021

A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status

1 reference

7 January 2021

A review of the assessment of antidepressant-induced sexual dysfunction used in randomized, controlled clinical trials

1 reference

7 January 2021

A rating scale for depression

1 reference

7 January 2021

1 reference

7 January 2021

A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.

1 reference

7 January 2021

The Arizona Sexual Experience Scale (ASEX): reliability and validity

1 reference

7 January 2021

ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder

1 reference

7 January 2021

Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study

1 reference

7 January 2021

Tolerability and safety aspects of mirtazapine

1 reference

7 January 2021

Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors.

1 reference

7 January 2021

Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.

1 reference

7 January 2021

Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study

1 reference

7 January 2021

Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis

1 reference

7 January 2021

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

1 reference

7 January 2021

A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder

1 reference

7 January 2021

Optimizing treatment in social phobia: a review of treatment resistance.

1 reference

7 January 2021

Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.1165

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23055414%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference